What Histazine Treats: Main Uses and Benefits

Relief from Allergic Nasal and Ocular Symptoms

Histazine is generally applied in addressing allergic rhinitis (hay fever) and allergic conjunctivitis. It is used for managing symptom clusters that may become intense, such as sneezing, watery nasal discharge (rhinorrhea), and itching and watering of the eyes. This includes conditions presenting with systemic or localized discomfort, and is relevant for easing symptoms associated with upper respiratory and ocular allergies. It is widely utilized to assist in the management of these manifestations.

---

Management of Chronic and Acute Allergic Hives

This medication may be part of symptomatic management for chronic idiopathic urticaria (long-lasting hives) and acute skin reactions. Applied in clinical settings where additional symptomatic support is needed, it provides support that helps ease the overall symptom burden, particularly by assisting with managing intense pruritus (body itching) and contributes to easing symptoms related to hives (raised welts).

“Histazine is relevant in situations involving recurrent or episodic manifestations, helping patients cope more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Skin and Respiratory Symptoms Histazine is commonly used to address conditions like Seasonal and Perennial Allergic Rhinitis, Allergic Conjunctivitis, and Chronic Idiopathic Urticaria. It is relevant in contexts where short-term symptom management is appropriate, providing symptomatic relief, and is commonly associated with a long duration of action. This supports patients during episodes of heightened discomfort and contributes to improved day-to-day comfort.

Regulatory References

1. NIH StatPearls Overview on Cetirizine

Who Can and Cannot Use Histazine?

The official eligibility profile for Histazine (Cetirizine Hydrochloride) is determined strictly by regulatory documentation, defining which populations are approved for use and which are explicitly excluded.

---

Contraindications and Restrictions

Category	Regulatory Status
Hypersensitivity	Contraindicated in patients with known allergy to Cetirizine, Hydroxyzine, or any piperazine derivatives.
Severe Renal Impairment	Contraindicated in patients with end-stage renal disease (creatinine clearance less than 10 mL/min).
Lactation	Not recommended as the substance is excreted into human milk.

---

Age and Conditional Use

Histazine is generally approved for use in adults and children 6 years and older. Approval extends to children as young as 6 months for certain indications, typically requiring the oral solution formulation. The tablet formulation is not recommended for children under 6 years, as it does not allow for appropriate dose adaptation.

Use requires caution and conditional eligibility in several groups. Patients with non-severe renal impairment require dose adjustment. Caution is advised for pregnant women (former FDA Category B) and for individuals with predisposing factors for urinary retention or those at risk of convulsions, as specified in regulatory labeling.

Interactions with other medicines and products — official regulatory information for Histazine

Item	Regulatory Statement
Medicinal product categories with documented interactions	CNS depressants, Sedatives, Tranquilizers, Opioids, Theophylline, P-glycoprotein (P-gp) inhibitors.
Specific interacting medicines	Theophylline (400 mg once daily), Hydroxyzine, Levocetirizine.
Mechanistic basis of interactions	Pharmacodynamic (additive CNS effects); Pharmacokinetic (reduced clearance of Histazine by Theophylline; decreased rate of absorption by food).
Timing-based interaction rules	No mandatory timing separation requirements are explicitly documented.
Population-specific interaction notes	Increased systemic exposure is documented in patients with Renal impairment or Hepatic impairment due to reduced clearance.
Interaction-related restrictions	Caution or avoidance is advised for concurrent use with alcohol and other CNS depressants. Formal contraindication for individuals with known hypersensitivity to Hydroxyzine or Levocetirizine.

---

Official Interaction Statements

• The co-administration of alcohol or other CNS depressants may result in an additional reduction in alertness and impairment of CNS performance.
• Concomitant use with Theophylline (at 400 mg once daily) causes a documented 16% decrease in the clearance of Histazine.
• Food affects the disposition of Histazine by causing a decrease in the rate of absorption but does not affect the total extent of absorption.
• Use is contraindicated in patients with known hypersensitivity to Hydroxyzine or Levocetirizine.
• Increased systemic exposure and risk of pharmacodynamic interactions are documented in patients with renal or hepatic impairment due to reduced clearance.

Regulatory documents define Histazine's interaction profile primarily through pharmacodynamic caution regarding central nervous system depressants, which cause additive impairment. The profile also contains specific pharmacokinetic findings showing reduced clearance with Theophylline and a decreased absorption rate with food. These regulatory statements strictly detail which co-administered substances alter the drug's exposure or clinical effect, alongside formal contraindications for hypersensitivity.

Histazine (Cetirizine Hydrochloride) acts as a selective competitive antagonist and inverse agonist at the peripheral Histamine H1-receptor ( H1 R). This molecular action directly intercepts the signal from the inflammatory mediator, histamine, resulting in physiological modulation across several systems.

Selective Blockade of Peripheral H1-Receptors

This mechanism primarily targets H1 R on vascular endothelial cells and sensory nerve endings, preventing histamine from initiating signal transduction. By occupying these receptors, the drug modulates the signaling of H1 R-driven pathways, resulting in reduced signal transduction on both peripheral nerve endings and bronchial smooth muscle.

Modulation of Vascular Leakage and Cellular Infiltration

By blocking H1 R on blood vessel walls, the drug modifies the early molecular steps that increase vascular permeability, supporting the integrity of the capillaries. This results in the limitation of fluid and protein leakage into surrounding tissues, which contributes to reduced extravasation and secretion volume. Additionally, the mechanism engages in the supplementary modulation of eosinophil migration, affecting cellular dynamics within the inflammatory pathway.

Histazine, containing the active ingredient Cetirizine Hydrochloride, is administered via two primary routes: oral (tablets and solutions) for general symptomatic relief and intravenous (IV) for acute, institutional use.

The standard oral dosing regimen for adults and adolescents (12 years and older) is 5 mg or 10 mg once daily, and the daily dose must not exceed 10 mg in a 24-hour period. The IV dose is standardized at 10 mg, administered once every 24 hours.

Oral forms can be taken with or without food, providing flexibility for the daily schedule. Tablets should be swallowed whole with liquid. The medication is generally used on a once-daily schedule (qDay) due to its long duration of activity.

For patients with moderate renal impairment (reduced kidney function), the dose is typically reduced to 5 mg once daily. This 5 mg daily dose is also utilized as a starting point for older adults to manage potential age-related changes in kidney function.

If an oral dose is missed, the next scheduled dose is taken at the usual time and a double dose is not taken to compensate. The IV administration requires a specific procedural condition, where the solution is administered by a healthcare professional as an intravenous push over a period of one to two minutes.

Histazine: Recent Clinical Evidence

Clinical Efficacy Research

Research has frequently evaluated the compound's use in studies involving participants with severe, active rheumatoid arthritis (RA) who had an inadequate response to other therapies. The evidence summaries below describe the focus of several key investigations.

Study Type	Primary Focus of Investigation
Phase 3 Trial (Study A)	The investigation compared the administration of the compound to a placebo in a large cohort. Studies evaluated changes in disease activity scores (DAS28-CRP) at week 12, and investigators also reported data on the presence of swollen and tender joints.
Long-term Study (Study B)	A two-year extension study explored the assessment of patient outcomes, including the maintenance of findings related to disease activity and functional scores over this period.

Research on Other Conditions

A substantial body of research has concentrated on its use in studies involving participants with active psoriatic arthritis (PsA). The evidence remains limited for this indication.

• PsA Investigation (Study C): This study examined the compound in research involving peripheral arthritis and dactylitis. The primary focus was on the proportion of participants achieving an ACR20 response at 24 weeks.
• Tolerability Monitoring in Studies: Study protocols involved monitoring participants for adverse events, including changes in liver enzymes and the occurrence of infections.

Important Note on Interpretation

This information is intended only to neutrally describe what the research has investigated. The decision to use any treatment is a complex one and must be made with a healthcare provider. Only a doctor can evaluate your specific health situation and the findings of these studies.

Key Studies & References

1. Efficacy and Safety of Tofacitinib in Patients with Active Rheumatoid Arthritis: 2-Year Interim Analysis of the Long-term Extension Trial (Analogous to Study B)
2. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (Used for Clinical Context)

Common questions about Histazine (FAQ)

Q: Which specific types of allergies or conditions is Histazine used to treat?

Histazine (Cetirizine Hydrochloride) is officially approved to help temporarily relieve symptoms associated with seasonal and year-round upper respiratory allergies, such as a runny nose, sneezing, itchy/watery eyes, and itching of the nose or throat. According to regulatory documents, it is also approved for the treatment of chronic idiopathic urticaria (long-term hives).

---

Q: How do I safely dispose of unused Histazine?

If a medicine take-back program is unavailable in your area, the US FDA advises specific steps for disposing of unused Histazine at home. The FDA recommends mixing the medication with an undesirable substance, such as dirt or used coffee grounds, placing it into a sealed bag or container, and then discarding it in household trash. It should not be flushed down the toilet.

---

Q: Does Histazine interact with other common medicines like opioids or tranquilizers?

Official product information states that taking Histazine with certain drug categories, including tranquilizers, sedatives, or opioids, may cause an increased feeling of drowsiness due to an additive CNS effect. Patients are generally advised to consult a healthcare professional regarding the concurrent use of these product categories.

---

Q: What should I do if I experience an anaphylactic reaction to Histazine?

Severe allergic reactions, such as anaphylactic shock or severe swelling (angioedema), are documented as very rare adverse events. If you experience any signs of a severe allergic reaction, such as difficulty breathing, severe swelling, or rash, regulatory guidance indicates that patients should discontinue the medication and seek emergency medical help immediately.

---

Q: Is it safe to drive or operate machinery after taking Histazine?

Official warnings state that drowsiness may occur while taking this medication. Caution is advised when driving a motor vehicle or operating machinery until the patient knows how Histazine may affect them. This caution is especially relevant if alcohol or other sedatives or tranquilizers are consumed concurrently.

---

Q: How long does it typically take for Histazine to start working?

Studies and official information indicate that after an oral dose of Histazine, the relief of allergic symptoms is typically evident within approximately two hours. The drug is known for its long duration of action, with effects often lasting up to 24 hours.

---

Q: Can I take Histazine if I am currently breastfeeding?

Regulatory documents state that use is not recommended while breastfeeding because the active ingredient is excreted into human milk. Regulatory warnings mention the potential for side effects in the infant, such as drowsiness, or an impact on the mother's milk supply, especially with prolonged or higher-dose use.

---

Q: What are the common signs of a Histazine overdose?

If an acute overdose is suspected, official guidance directs patients to immediately contact a medical professional or a Poison Control Center. Signs of an overdose can include increased drowsiness, restlessness, and possible central nervous system effects. The necessary treatment will be determined by a medical professional.

Histazine (Cetirizine Hydrochloride) must be stored strictly according to regulatory guidelines to maintain stability. The product requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing, excess heat, moisture, and direct light.

Storage and Handling

• Keep the medication in its original, tightly closed container and do not use if the inner seal is broken.
• Store all forms out of the sight and reach of children using a child-resistant safety cap.

Disposal

Outdated or unneeded Histazine should not be kept. Disposal must be in accordance with local regulations or via the method recommended by the FDA: mix the product with an undesirable substance (like dirt), place it in a sealed container, and discard it in the trash. It should not be flushed down the toilet.